The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism

Stem Cells

Volumn 34, Issue 12, 2016, Pages 2916-2929

  Moore, Joseph B ^a   Zhao, John ^a   Keith, Matthew C L ^a   Amraotkar, Alok R ^a   Wysoczynski, Marcin ^a   Hong, Kyung U ^a   Bolli, Roberto ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cardiac mesenchymal stromal cells; Cardiogenic differentiation; Cardiogenic gene expression; Histone deacetylase inhibitors; Histone deacetylases; p53; Vasculogenic differentiation

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; HISTONE H3; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2C; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR TBX5; TRANSCRIPTION FACTOR TBX5B; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HDAC1 PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE INHIBITOR;

ARTICLE; CARDIAC MUSCLE CELL; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; EPIGENETICS; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENETIC SCREENING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MESENCHYMAL STROMA CELL; MUSCLE CELL; NORMAL HUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SMOOTH MUSCLE CELL; TRANSCRIPTION REGULATION; ACETYLATION; ANGIOGENESIS; ANTIBODY SPECIFICITY; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; METABOLISM;

ACETYLATION; BIOMARKERS; BUTYRIC ACID; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; IMMUNOPHENOTYPING; MESENCHYMAL STROMAL CELLS; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; ORGAN SPECIFICITY; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84992126902     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2471     Document Type: Article

References (44)

1. Bolli R, Chugh AR, D'amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet 2011;378:1847–1857.
2. Chugh AR, Beache GM, Loughran JH et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: The SCIPIO trial: Surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012;126:S54–S64.
3. Vrtovec B, Poglajen G, Lezaic L et al. Comparison of transendocardial and intracoronary CD34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013;128:S42–S49.
4. Vrtovec B, Poglajen G, Lezaic L et al. Effects of intracoronary CD34(+) stem cell transplantation in nonischemic dilated cardiomyopathy patients 5-year follow-up. Circ Res 2013;112:165–173.
5. Sanganalmath SK, Bolli R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013;113:810–834.
6. Hong KU, Li QH, Guo YR et al. A highly sensitive and accurate method to quantify absolute numbers of c-kit plus cardiac stem cells following transplantation in mice. Basic Res Cardiol 2013;108:
7. Keith MCL, Bolli R. “String Theory” of c-kit(pos) cardiac cells a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ Res 2015;116:1216–1230.
8. Yoon CH, Koyanagi M, Iekushi K et al. Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: Role of cardiovascular lineage commitment. Circulation 2010;121:2001–2011.
9. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701–705.
10. Behfar A, Yamada S, Crespo-Diaz R et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010;56:721–734.
11. Gnecchi M, Zhang ZP, Ni AG et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204–1219.
12. Rossini A, Frati C, Lagrasta C et al. Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin. Cardiovasc Res 2011;89:650–660.
13. Ubil E, Duan J, Pillai IC et al. Mesenchymal-endothelial transition contributes to cardiac neovascularization. Nature 2014;514:585–590.
14. Leu YW, Huang TH, Hsiao SH. Epigenetic reprogramming of mesenchymal stem cells. Adv Exp Med Biol 2013;754:195–211.
15. Oyama T, Nagai T, Wada H et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol 2007;176:329–341.
16. Yang G, Tian J, Feng C et al. Trichostatin A promotes cardiomyocyte differentiation of rat mesenchymal stem cells after 5-azacytidine induction or during coculture with neonatal cardiomyocytes via a mechanism independent of histone deacetylase inhibition. Cell Transplant 2012;21:985–996.
17. Zhang LX, DeNicola M, Qin X et al. Specific inhibition of HDAC4 in cardiac progenitor cells enhances myocardial repairs. Am J Physiol Cell Physiol 2014;307:C358–C372.
18. Gao CZ, Liu Y, Lam M et al. Histone deacetylase 7 (HDAC7) regulates myocyte migration and differentiation. Biochim Biophys Acta Mol Cell Res 2010;1803:1186–1197.
19. Lu DF, Yao Y, Su ZZ et al. Downregulation of HDAC1 is involved in the cardiomyocyte differentiation from mesenchymal stem cells in a myocardial microenvironment. Plos One 2014;9:
20. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007;26:5541–5552.
21. Hochedlinger K, Plath K. Epigenetic reprogramming and induced pluripotency. Development 2009;136:509–523.
22. Kretsovali A, Hadjimichael C, Charmpilas N. Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int 2012;2012:1–10.
23. Keeney M, Gratama JW, Chin-Yee IH et al. Isotype controls in the analysis of lymphocytes and CD34+ stem and progenitor cells by flow cytometry - Time to let go! Cytometry 1998;34:280–283.
24. O'gorman MRG, Thomas J. Isotype controls - Time to let go? Cytometry 1999;38:78–80.
25. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763–776.
26. Montesinos JJ, Flores-Figueroa E, Castillo-Medina S et al. Human mesenchymal stromal cells from adult and neonatal sources: Comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy 2009;11:163–176.
27. Kruh J. Effects of sodium-butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982;42:65–82.
28. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 2009;10:32–42.
29. Ruau D, Ensenat-Waser R, Dinger TC et al. Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells. Stem Cells 2008;26:920–926.
30. Yamanegi K, Kawabe M, Futani H et al. Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells. Int J Oncol 2015;46:1994–2002.
31. Duran JM, Makarewich CA, Sharp TE et al. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms. Circ Res 2013;113:539–552.
32. Bearzi C, Rota M, Hosoda T et al. Human cardiac stem cells. Proc Natl Acad Sci USA 2007;104:14068–14073.
33. D'amario D, Fiorini C, Campbell PM et al. Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies. Circ Res 2011;108:857–861.
34. Hu ED, Dul E, Sung CM et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003;307:720–728.
35. Georges R, Nemer G, Morin M et al. Distinct expression and function of alternatively spliced Tbx5 isoforms in cell growth and differentiation. Mol Cell Biol 2008;28:4052–4067.
36. Ito A, Kawaguchi Y, Lai CH et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002;21:6236–6245.
37. Zhao Y, Lu S, Wu L et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006;26:2782–2790.
38. Hsieh J, Nakashima K, Kuwabara T et al. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci USA 2004;101:16659–16664.
39. Haumaitre C, Lenoir O Scharfmann R. Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors. Mol Cell Biol 2008;28:6373–6383.
40. Molchadsky A, Rivlin N, Brosh R et al. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 2010;31:1501–1508.
41. Hadjal Y, Hadadeh O, Yazidi CE et al. A p38MAPK-p53 cascade regulates mesodermal differentiation and neurogenesis of embryonic stem cells. Cell Death Dis 2013;4:e737.
42. Soddu S, Blandino G, Scardigli R et al. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol 1996;134:193–204.
43. Mazzaro G, Bossi G, Coen S et al. The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells. Oncogene 1999;18:5831–5835.
44. Halevy O. P53 Gene is up-regulated during skeletal-muscle cell-differentiation. Biochem Biophys Res Commun 1993;192:714–719.